suramin has been researched along with Diabetic Nephropathies in 6 studies
Suramin: A polyanionic compound with an unknown mechanism of action. It is used parenterally in the treatment of African trypanosomiasis and it has been used clinically with diethylcarbamazine to kill the adult Onchocerca. (From AMA Drug Evaluations Annual, 1992, p1643) It has also been shown to have potent antineoplastic properties.
suramin : A member of the class of phenylureas that is urea in which each of the amino groups has been substituted by a 3-({2-methyl-5-[(4,6,8-trisulfo-1-naphthyl)carbamoyl]phenyl}carbamoyl)phenyl group. An activator of both the rabbit skeletal muscle RyR1 and sheep cardiac RyR2 isoform ryanodine receptor channels, it has been used for the treatment of human African trypanosomiasis for over 100 years.
Diabetic Nephropathies: KIDNEY injuries associated with diabetes mellitus and affecting KIDNEY GLOMERULUS; ARTERIOLES; KIDNEY TUBULES; and the interstitium. Clinical signs include persistent PROTEINURIA, from microalbuminuria progressing to ALBUMINURIA of greater than 300 mg/24 h, leading to reduced GLOMERULAR FILTRATION RATE and END-STAGE RENAL DISEASE.
Excerpt | Relevance | Reference |
---|---|---|
"Suramin treatment significantly suppressed the increase in the urinary albumin-to-creatinine ratio, glomerular hypertrophy, mesangial matrix expansion, and glomerular fibrosis in KK-Ay mice." | 1.91 | Suramin prevents the development of diabetic kidney disease by inhibiting NLRP3 inflammasome activation in KK-Ay mice. ( Kodera, R; Miyamoto, S; Oda, K; Shikata, K; Wada, J, 2023) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (33.33) | 24.3611 |
2020's | 4 (66.67) | 2.80 |
Authors | Studies |
---|---|
Oda, K | 1 |
Miyamoto, S | 1 |
Kodera, R | 1 |
Wada, J | 1 |
Shikata, K | 1 |
Chyła-Danił, G | 1 |
Sałaga-Zaleska, K | 3 |
Kreft, E | 2 |
Stumski, O | 1 |
Krzesińska, A | 1 |
Sakowicz-Burkiewicz, M | 1 |
Kuchta, A | 3 |
Jankowski, M | 3 |
Chyła, G | 2 |
Dąbkowski, K | 2 |
Pikul, P | 1 |
Herman, S | 1 |
Lenartowicz, M | 1 |
Korrapati, MC | 2 |
Howell, LA | 1 |
Howell, LH | 1 |
Shaner, BE | 2 |
Megyesi, JK | 1 |
Siskind, LJ | 1 |
Schnellmann, RG | 2 |
Neely, BA | 1 |
Alge, JL | 1 |
Arthur, JM | 1 |
6 other studies available for suramin and Diabetic Nephropathies
Article | Year |
---|---|
Suramin prevents the development of diabetic kidney disease by inhibiting NLRP3 inflammasome activation in KK-Ay mice.
Topics: Adenosine Triphosphate; Animals; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Inflammasomes; I | 2023 |
Long-Term Effects of Suramin on Renal Function in Streptozotocin-Induced Diabetes in Rats.
Topics: Acetylcholine; Albumins; Animals; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Kidney; N | 2023 |
Suramin enhances the urinary excretion of VEGF-A in normoglycemic and streptozotocin-induced diabetic rats.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Kidney; Male; Matri | 2021 |
Effect of suramin on urinary excretion of diabetes-induced glomerular and tubular injury parameters in rats.
Topics: Animals; Biomarkers; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Kidney Glomerulus; Mal | 2021 |
Suramin: a potential therapy for diabetic nephropathy.
Topics: Actins; Animals; Collagen Type I; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Models, | 2013 |
Diabetes-induced renal injury in rats is attenuated by suramin.
Topics: Animals; Biomarkers; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Intercellular Adhesion | 2012 |